Investors who bought into Annovis Bio following Friday’s news of a mid-stage hit in Alzheimer’s disease may have acted a little precipitately. The company trumpeted a significant improvement in cognitive symptoms of the disease with ANVS401, and its stock leapt 127% to close at $60.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,